Accumulating evidence has demonstrated that aberrant expression and activity of STAT3 are implicated in both cancer stem cell (CSC) expansion and associated drug resistance in several cancer types, including breast and gastric cancer [22-25], suggesting that STAT3 may contribute to trastuzumab resistance in HER2-positive solid cancer. This evidence concerns the gene ERBB2 and gastric cancer.